- Home
- SOND vs KPTI Comparison
SOND vs KPTI Comparison
Compare SOND & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOND
- KPTI
- Stock Information
- Founded
- SOND 2014
- KPTI 2008
- Country
- SOND United States
- KPTI United States
- Employees
- SOND N/A
- KPTI N/A
- Industry
- SOND Hotels/Resorts
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SOND Consumer Discretionary
- KPTI Health Care
- Exchange
- SOND Nasdaq
- KPTI Nasdaq
- Market Cap
- SOND 30.3M
- KPTI 33.6M
- IPO Year
- SOND N/A
- KPTI 2013
- Fundamental
- Price
- SOND $2.37
- KPTI $6.27
- Analyst Decision
- SOND
- KPTI Strong Buy
- Analyst Count
- SOND 0
- KPTI 5
- Target Price
- SOND N/A
- KPTI $61.00
- AVG Volume (30 Days)
- SOND 25.0K
- KPTI 154.7K
- Earning Date
- SOND 04-29-2025
- KPTI 05-07-2025
- Dividend Yield
- SOND N/A
- KPTI N/A
- EPS Growth
- SOND N/A
- KPTI N/A
- EPS
- SOND N/A
- KPTI N/A
- Revenue
- SOND $624,458,000.00
- KPTI $145,237,000.00
- Revenue This Year
- SOND $28.50
- KPTI $4.87
- Revenue Next Year
- SOND $17.62
- KPTI $16.29
- P/E Ratio
- SOND N/A
- KPTI N/A
- Revenue Growth
- SOND 8.32
- KPTI N/A
- 52 Week Low
- SOND $0.88
- KPTI $3.51
- 52 Week High
- SOND $10.50
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- SOND 52.34
- KPTI 62.17
- Support Level
- SOND $2.23
- KPTI $3.83
- Resistance Level
- SOND $2.97
- KPTI $4.36
- Average True Range (ATR)
- SOND 0.27
- KPTI 0.45
- MACD
- SOND 0.05
- KPTI 0.39
- Stochastic Oscillator
- SOND 53.10
- KPTI 90.49
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.